Li Jingguo, Yang Zhengyi, Tuo Biguang
Department of Gastroenterology, Affiliated Hospital, Zunyi Medical University, Zunyi, People's Republic of China.
Department of Gastroenterology, Bijie First People's Hospital, Bijie, Guizhou Province, People's Republic of China.
Onco Targets Ther. 2019 Jul 25;12:6013-6022. doi: 10.2147/OTT.S212088. eCollection 2019.
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers causing death worldwide. It is difficult to detect at an early stage and most patients with advanced HCC rarely achieve satisfying therapeutic results. Accordingly, researchers have been trying to find new biomarkers for diagnosis and new methods of treatment. OCT1, a member of solute carrier super family, is highly expressed in normal liver tissues, and predominantly transports endogenous and exogenous substances, such as metabolites, drugs and toxins to hepatocytes. Studies have demonstrated that the expression of OCT1 is related to the progression and survival of HCC patients. Furthermore, sorafenib, which is regarded as the only effective molecular targeting drug for advanced HCC, is affected by OCT1 variants. In the current review, we summarized the reports about OCT1 and HCC in order to present a comprehensive overview of the relationship between OCT1 and HCC.
肝细胞癌（HCC）是全球最常被诊断出的导致死亡的癌症之一。它在早期很难被检测到，大多数晚期HCC患者很少能获得令人满意的治疗效果。因此，研究人员一直在努力寻找新的诊断生物标志物和新的治疗方法。OCT1是溶质载体超家族的成员之一，在正常肝组织中高表达，主要将内源性和外源性物质，如代谢物、药物和毒素转运至肝细胞。研究表明，OCT1的表达与HCC患者的病情进展和生存情况相关。此外，索拉非尼被认为是晚期HCC唯一有效的分子靶向药物，它会受到OCT1变体的影响。在本综述中，我们总结了关于OCT1和HCC的报告，以便全面概述OCT1与HCC之间的关系。
